UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1344-5
Program Prior Authorization/Notification
Medication Apokyn® (apomorphine) injection
P&T Approval Date 12/2020, 12/2021, 12/2022, 12/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Apokyn is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of
hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off”
episodes) associated with advanced Parkinson’s disease.
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Apokyn will be approved based on both of the following:
a. Diagnosis of Parkinson’s disease
-AND-
b. Used as intermittent treatment for OFF episodes
Authorization will be issued for 6 months.
B. Reauthorization
1. Apokyn will be approved based on the following criteria:
a. Documentation of positive clinical response to Apokyn therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
© 2024 UnitedHealthcare Services, Inc.
1
• Supply limits and/or Medical Necessity may be in place.
4. References:
1. Apokyn [package insert]. Rockville, MD: MDD US Operations, LLC; June 2022.
Program Prior Authorization/Notification - Apokyn (apomorphine) injection
Change Control
12/2020 New program
12/2021 Annual review with no changes.
12/2022 Annual review with no changes to clinical coverage criteria. Added
state mandate footnote and updated reference.
12/2023 Annual review with no changes to coverage criteria.
12/2024 Annual review with no changes to coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
2